Form D · Pharmaceuticals
Natsar Pharmaceuticals, Inc.
Ellicott City, MD · CIK 0002134002
Offering snapshot reported May 8, 2026 · SEC filing
- Reported sold
- $4.22M Indefinite offering
- Investors reported
- 15 Form D · investor count
- Minimum accepted
- $1 Reported outside-investor minimum
- First sale
- Apr 23, 2026 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| May 8, 2026 | Initial | $4,221,000 | No comparison | 15 | SEC filing |
Offering details
- Securities
- Equity, Tenant in common
- Exemptions
- 06b
- Duration over one year
- Yes
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-583294
Source: Form D, filed May 8, 2026. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Venu Raman | Director, Executive |
Issuer details
Industry: Pharmaceuticals (See others in industry)
Address:
4624 Tall Maple Ct.
Ellicott City, MD, 21043
Ellicott City, MD, 21043